JW THERAP-B (02126) grants Juno non-exclusive license to JW's sLVV production process and related technical knowledge.

JW THERAP-B (02126) announced that the company has entered into a licensing agreement with one of its major shareholders and related party Juno on April 18, 2025 (Eastern Time). Under the agreement, the company grants Juno a non-exclusive license to JW sLVV manufacturing process and related technical knowledge (and patents, if applicable at any time during the term of the license agreement), which are mainly or directly related to the development, commercialization, manufacturing, or contract manufacturing of Juno's cell therapy products on a global scale, or is reasonably necessary or useful for them. The total consideration that Juno is required to pay the company under the license agreement shall not exceed $10 million.